Final-Program-ATS-2023-AP.vp

TUESDAY • MAY 23

299

908 Correlation of Lung Function Using Forced Oscillation Technique With Spirometry in Children Aged (4-18 Years) With Cystic Fibrosis (CF) and Non CF Bronchiectasis/ S. Singh, Chandigarh, India 909 Diagnosis Accuracy and Crosschecking Data Entries in Medical Records and Cystic Fibrosis Foundation Patient Registry: A Quality Improvement Project/ K. Agoramurthi, Little Rock, AR 910 Effect of Disinfection With Baby-bottle Sterilizer of Reusable Breath-enhanced Nebulizers on Aerosolized Albuterol Output and Characteristics/ K. Agoramurthi, Little Rock, AR 911 Variability of Physiologic Testing and Magnetic Resonance Imaging Outcomes in Paediatric Populations/ V.M. Diamond, Vancouver, Canada 912 Bronchiectasis and Other Abnormal Computer Tomographic Chest Scan Findings in Paediatric Spinal Muscular Atrophy/ A. Chacko, Brisbane, Australia 913 Treatment Response to Pulmonary Exacerbation in Primary Ciliary Dyskinesia/ D. Gatt, Toronto, Canada 914 Genotype-phenotype Correlations of Primary Ciliary Dyskinesia in Siblings/ D. Gatt, Beer-Sheva, Israel 915 Inclusivity of the North American Primary Ciliary Dyskinesia (PCD) Foundation Clinical Registry/ M.G. O’Connor, Nashville, TN 916 Genotype to Phenotype: Measuring Mucociliary Clearance in Primary Ciliary Dyskinesia/ S. Abu-Nasser, Chapel Hill, NC 917 Mild Phenotypes in French-Canadians With TT25-related Primary Ciliary Dyskinesia/ M.K. Palani, Montreal, Canada 918 The Utility of Nasal Nitric Oxide in the Diagnostic Evaluation of Primary Ciliary Dyskinesia/ K.A. Carr, Nashville, TN 919 Intra-day Test-retest Reliability of Multiple Breath Washout in Pediatric Primary Ciliary Dyskinesia/ W.B. Wee, Toronto, Canada 920 Primary Ciliary Dyskinesia In Patients With CCNO Variants: A Case Series/ K.A. Despotes, Chapel Hill, NC 921 Improvement of Lung Function After Implementation of Standardized Cystic Fibrosis Care Algorithm: Quality Improvement Project-International Collaboration/ Y. Gökdemir, Istanbul, Turkey

721 A Case of Probable Invasive Pulmonary Aspergillosis (IPA) Diagnosed by Bronchoscopy/ S. Qureshi, Philadelphia, PA 722 Vibrio Vulnificus Necrotizing Fasciitis Leading to Septic Shock and Multiorgan Failure/ Z. Ng, Lafayette, LA 723 Human Herpesvirus 6 Encephalitis in an Immunocompetent Adult/ N. Touloumes, Louisville, KY 724 Severe Monkeypox With Airway Compromise Requiring Emergent Cricothyroidotomy/ R.C. Flowers, New York, NY

BASIC • CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

C106 OUT OF THE ‘MUC’: UPDATES IN PCD AND CF 2:15 p.m. - 4:15 p.m. Marriott Marquis Washington Marquis Ballroom, Salons 3-4 (Level M2) Poster Viewing 2:15-3:00 Discussion 3:00-4:15 Chairing: M.E. Mcgarry, MD, San Francisco, CA S. Das, DO, Houston, TX S.L. Martiniano, MD, MS, Aurora, CO 901 Transcriptomic Prediction of Clinical Response to Trikafta in Patients With Cystic Fibrosis/ M. Yue, Pittsburgh, PA 902 Tracking Regional Changes in CF Lung Disease After 1 Day of Airway-clearance Withdrawal, Using UTE and Xe MRI/ M.E. West, Cincinnati, OH 903 Breathing Pattern During Sleep and Its Relationship With Expiratory Forced Volume in 1 Second in Pediatric Patients With Cystic Fibrosis Who Live at High Altitude/ M.I. Escamilla, Bogota, Colombia 904 Linezolid Resistant Staphylococcus Aureus in Patients With Cystic Fibrosis/ A.J. Fischer, Iowa City, IA 905 The Effect of CFTR Modulator Therapies on Inpatient Treatment for Acute Pulmonary Exacerbations in Cystic Fibrosis/ M. Haag, Portland, OR 906 Improved Diagnosis of Early Aspergillus Lung Disease in CF (IDEAL) Study Design and First Results/ F. Mollica, Rotterdam, Netherlands 907 The Predictive Value of Neutrohil Lymphocyte Ratio in Cystic Fibrosis Exacerbations: Pilot Study/ O. Yilmaz, Manisa, Turkey

ATS 2023 • Washington, DC